

## Title of Project

Engineering of *Chlamydomonas reinhardtii* to produce betalain pigments and the use of riboswitches to direct metabolic flux.

## Team contacts

Alfonso Timoneda Monfort  
Department of Plant Sciences, University of Cambridge  
at656@cam.ac.uk

Dr Payam Mehrshahi  
Department of Plant Sciences, University of Cambridge  
pm579@cam.ac.uk

Dr Samuel Brockington (sponsor)  
Lecturer in Evolution and Diversity & Curator of the Cambridge University Botanic Gardens  
Department of Plant Sciences, University of Cambridge  
sb771@cam.ac.uk

## Summary

Betalain pigments are plant metabolites showing a wide variety of potential applications in the pharmaceutical, agricultural and food industry. Given the potential shown, it is important to further understand the biosynthetic processes leading to betalain production and accumulation in plants and how this knowledge can be used to engineer new industrial production hosts using model organisms like microalgae. We proposed to heterologously express the betalain biosynthetic pathway in *Chlamydomonas reinhardtii* with metabolic flux artificially regulated towards betacyanin or betaxanthin production by the use of riboswitches that respond to exogenous supplementation of culture media with thiamine and hydroxyethyl thiazole (HET). Such riboswitch-driven regulation of the branch point enzymes would allow the ratio of cyclo-DOPA to betalamic acid to be “controlled” and thereby selectively shift the overall coloration produced towards the red or the yellow spectra respectively. We have synthesised the sequences of five betalain biosynthetic genes (CYP76AD1, CYP76AD6, DODA $\alpha$ , and cDOPA5GT) previously domesticated and optimised to reflect codon usage in the nuclear genome of *C. reinhardtii*. We also isolated two recently published constitutive promoter and terminator combinations that constitute new tools for gene expression in *C. reinhardtii* (RPL23, FDX1). Five different multigene vectors were successfully assembled via MoClo Golden Gate cloning and transformed in the nuclear genome of *C. reinhardtii*. Selection and confirmation of expressing clones will be done in the near future and further analysis will determine riboswitch ability to modulate the betalain pathway.

## Report and outcomes

To produce *C. reinhardtii* strains that are able to produce betalains in a regulated manner, the following milestones had to be addressed.

### (1) Codon optimisation and gene synthesis

We synthesised the sequences of five betalain biosynthetic genes (CYP76AD1, CYP76AD6, DODA $\alpha$ , and cDOPA5GT) previously optimised to reflect codon usage in the nuclear genome of *C. reinhardtii*. *Beta vulgaris* transcript sequences were used as templates for the codon optimisation for all genes, except for cDOPA5GT which was retrieved from the *Mirabilis jalapa* transcriptome. Domestication was done against *Bpil*, *Bsal* and *SapI* restriction sites to ensure compatibility with MoClo and Loop Golden Gate assembly protocols. Synthesis, domestication and codon optimisation were performed by the *GeneArt* gene synthesis service provided by Thermo Fisher Scientific. In all cases, genes were synthesised with flanking regions containing compatible MoClo Golden Gate overhangs and *Bsal* restriction sites, and entry plasmids were generated including a kanamycin resistance gene. Plasmid design was performed in order to be able to be used directly as MoClo level 0 vectors.

See Table 1 for complete list of generated vectors.

### (2) Cloning of RPL23 and FDX1 promoter and terminator pairs

Shortly after starting the OpenPlant project, a report was published identifying new genic flanking sequences for improved transgenic expression in *C. reinhardtii* [1]. Initially, our list of available constitutive promoters for *Chlamydomonas* consisted of the well characterised HSP70:RBCS2 and PSAD. The amount of genes we were considering for our final multigene constructs and the low number of promoter/terminator pairs available translated into a considerable risk of silencing associated with the use of repetitive elements. We therefore aimed to isolate the recently characterised promoter and terminator sequences for the RPL23, RPL35 and FDX1 genes from *C. reinhardtii* genomic DNA. Primer design included the overhangs and *Bpil* restriction sites required for cloning into MoClo level 0 acceptors. Promoters were amplified using two different primer pairs, generating amplicons with either TACT or AATG 3' overhangs, for their use as promoter only or promoter plus 5'UTR parts respectively (Figure 1). Amplification was successful for promoter/terminator pairs of RPL23 and FDX1, and was followed by gel extraction and cloning to corresponding level 0 acceptors. This was enough to complete our multigene construct design and further attempts to isolate RPL35 flanking sites were not performed, but can be done in the future.

See Table 1 for complete list of generated vectors.

### (3) Multigene vector construction

Using the MoClo Golden Gate technology we assembled multigene cassettes for their use in transformation of the *Chlamydomonas* nuclear genome. Final vector design is detailed in Table 2 at the end of the document, and new level 1 cassettes were constructed accordingly. Due to the relatively high number of genes included in some of the level 2 vectors, these were designed to contain two antibiotic resistance genes (for bleomycin and paromomycin) flanking both sides of the constructs. Dual selection would therefore ensure introduction of both ends of the cassette in the genome and minimize the number of selected colonies with loss of cassette fragments. The use of riboswitch parts in some of the level 1 cassettes decreased the assembly efficiency possibly due to its three-dimensional structures. We therefore used commercial NEB5 $\alpha$  stable competent cells. Level 2 assemblies also proved themselves challenging probably due to vector complexity and had to be attempted through continuous repetitions and the optimization of part concentrations in some cases. All level 1 plasmids were checked by sequencing, and level 2 plasmids were checked by digestion with restriction enzymes (Figure 2) and sequencing of the cassette flanking regions.

See Table 1 for complete list of generated vectors.

### (4) Transformation of *Chlamydomonas reinhardtii*

*C. reinhardtii* strain uvm4 [2] has already been transformed by electroporation with the developed vectors. Transformants will undergo selection by growth in TAP media containing zeocin and paromomycin.

### (5) Strain characterization and riboswitch activation and tuning

After transformation of *C. reinhardtii* the following scenarios can be encountered:

#### (5.1) Pigmented colonies appear.

Gene presence and expression levels will be assessed by PCR and qPCR. Betalain production and composition in transgenic *C. reinhardtii* lines will be analysed using a spectrophotometer by measuring absorbance of betacyanins and betaxanthins at 540nm and 475nm respectively. Experiments to assess riboswitch ability to direct metabolic flux to either branch of the betalain pathway will be performed once the transgenic lines have been identified.

#### (5.2) Transformed *C. reinhardtii* strains don't produce any coloration.

Gene presence on resistant colonies can be assessed by PCR to confirm integration of all the parts of our multigene cassette. In the cases where all genes are present, expression levels can be quantified by qPCR to rule out silencing of one or several of the transgenes. If these are as expected, new constructs with tagged versions of our transgenes should be designed to confirm protein presence and localisation.

#### (5.3) No colonies survive the selection process.

Transformation of *C. reinhardtii* would be repeated to rule out possible experimental errors. It is possible that one or more intermediates of the betalain pathway, or even pigment concentration itself, could have toxic effects on microalgae. To account for this possibility, transformation of *C. reinhardtii* with our riboswitch containing vector could be repeated, but this time adding thiamine to the selection media. This would inactivate the pathway hence allowing for a normal development of resistant colonies. Later, the colonies would be subcultured into liquid media containing a reduced concentration of thiamine that allows basal level of gene expression and thereby allow the optimization of expression ratios that would overcome potential cytotoxicity.

## Expenditures

| Item                                                         | Supplier                | Price (£)        | Quantity | Catalog n  | Total price (+VAT) | Date            |
|--------------------------------------------------------------|-------------------------|------------------|----------|------------|--------------------|-----------------|
| Gene synthesis with GeneArt (OpenPlant)                      | ThermoFisher Scientific | 1517,43          | 1        | PD2627147  | 1820,92            | 12/10/2017      |
| OpenPlant Oligos for new Promoters                           | IDT                     | 94,98            | 1        | PD2644503  | 113,98             | 06/11/2017      |
| PCRBIO HiFi Polymerase, 200 Units                            | PCR Biosystems          | 69               | 1        | PB10.41-02 | 82,8               | 04/12/2017      |
| Macherey Nagel, NucleoSpin Plasmid, 250preps                 | Macherey Nagel          | 149,95           | 1        | 740588250  | 179,94             | 22/2/2018       |
| OpenPlant Oligos for sequencing                              | IDT                     | 23,94            | 1        | PD2675116  | 28,73              | 20/12/2017      |
| OpenPlant Oligos for sequencing 2                            | IDT                     | 3,24             | 1        | PD2690119  | 3,89               | 22/01/2018      |
| NEB® Stable Competent E coli (High Efficiency)               | NEB                     | 164,8            | 1        | C3040I     | 197,76             | 22/01/2018      |
| Gene Pulser/MicroPulser Cuvette, 0.4 cm gap, sterile, bag/50 | Bio-Rad                 | 114,95           | 1        | 1652088    | 137,94             | 22/02/2018      |
| Sequencing reactions                                         | Source Biosciences      | 4,5              | 94       |            | 507,60             | multiple        |
| <b>TOTAL</b>                                                 |                         |                  |          |            | <b>3073,55</b>     |                 |
|                                                              |                         |                  |          |            |                    |                 |
|                                                              |                         |                  |          |            | <b>SPENT (£)</b>   | <b>LEFT (£)</b> |
|                                                              |                         |                  |          |            | 3073,55            | 926,45          |
| <b>Expected future expenses</b>                              | Cost / element          | <b>Price (£)</b> |          |            |                    |                 |
| RNEasy Plant Mini Kit (2x)                                   | £ 209,85 / 50 rxn       | 419,7            |          |            |                    |                 |
| SuperScript III Full Kit                                     | £516.8 / 50 rxn         | 516,8            |          |            |                    |                 |
| <b>TOTAL</b>                                                 |                         | <b>936,5</b>     |          |            |                    |                 |

## Follow on plans

Following the selection process, betalain producing *C. reinhardtii* strains will be characterized and riboswitch efficacy to control protein ratios and ultimately the direction of metabolic flux towards red or yellow coloration will be assessed.

In order to facilitate the downstream analysis of the betalain compounds produced, extra funds provided would contribute to the purchase of a ZORBAX Eclipse XDB-C18 (5µm, 4.6 x 50 mm) column for its use in liquid chromatography (LC-MS) quantification and analysis.

The isolated FDX1 terminator contained an undomesticated *Bpil* site which interfered with the correct assembly of Level 2 cassettes. Extra funding could also be used for the synthesis of this part and RPL35 promoter and terminator regions in the case further cloning attempts were unsuccessful.

ZORBEX Eclipse XDB-C18 (5µm , 4.6 x 50 mm) – currently £257.55 in the University MarketPlace.

## References

- [1] López-Paz C, Liu D, Geng S and Umen JG. 2017. Identification of *Chlamydomonas reinhardtii* endogenous genic flanking sequences for improved transgene expression. *Plant J*, 92: 1232–1244.
- [2] Neupert J, Karcher D, Bock R. 2009. Generation of *Chlamydomonas* strains that efficiently express nuclear transgenes. *The Plant Journal*, 57: 1140–1150.

**Table 1.** Complete list of generated level 0, level 1 and level 2 vectors compatible with the MoClo Golden Gate cloning technology.

Level 0

| Vector ID        | Backbone         |               | Resistance    | Level 0 / Entry |                  |                                  |             |
|------------------|------------------|---------------|---------------|-----------------|------------------|----------------------------------|-------------|
|                  |                  |               |               | 5' overhang     | Contains         | Species                          | 3' overhang |
| pL0-ChcoDODAA    | GeneArt backbone | CDS           | Kanamycin     | AATG            | DODAA1           | <i>Chlamydomonas reinhardtii</i> | GCTT        |
| pL0-ChcoCYP76AD1 | GeneArt backbone | CDS           | Kanamycin     | AATG            | CYP76AD1         | <i>Chlamydomonas reinhardtii</i> | GCTT        |
| pL0-ChcoCYP76AD6 | GeneArt backbone | CDS           | Kanamycin     | AATG            | CYP76AD6         | <i>Chlamydomonas reinhardtii</i> | GCTT        |
| pL0-ChcocDOPA5GT | GeneArt backbone | CDS           | Kanamycin     | AATG            | cDOPA5GT         | <i>Chlamydomonas reinhardtii</i> | GCTT        |
| pL0ATOP1         | pICH41295        | Promoter      | Spectinomycin | GGAG            | RPL23 Promoter   | <i>Chlamydomonas reinhardtii</i> | TACT        |
| pL0ATOP2         | pICH41233        | Promoter-Ntag | Spectinomycin | GGAG            | RPL23 Promoter   | <i>Chlamydomonas reinhardtii</i> | AATG        |
| pL0ATOP5         | pICH41295        | Promoter      | Spectinomycin | GGAG            | FDX1 Promoter    | <i>Chlamydomonas reinhardtii</i> | TACT        |
| pL0ATOP6         | pICH41233        | Promoter-Ntag | Spectinomycin | GGAG            | FDX1 Promoter    | <i>Chlamydomonas reinhardtii</i> | AATG        |
| pL0ATOP7         | pICH41276        | Terminator    | Spectinomycin | GCTT            | RPL23 Terminator | <i>Chlamydomonas reinhardtii</i> | CGCT        |
| pL0ATOP8         | pICH41276        | Terminator    | Spectinomycin | GCTT            | FDX1 Terminator  | <i>Chlamydomonas reinhardtii</i> | CGCT        |

Level 1

| Vector ID | Backbone  |                | Resistance | Level 1 / Cassette (co = codon optimised) |             |              |        |            |
|-----------|-----------|----------------|------------|-------------------------------------------|-------------|--------------|--------|------------|
|           |           |                |            | Promoter                                  | NT-tag      | CDS          | CT-tag | Terminator |
| pL1ATBleR | pICH47802 | position 1 rev | Ampicillin | PSAD                                      |             | Bleomycin R  |        | PSAD       |
| pL1ATOP1  | pICH47742 | position 2 fwd | Ampicillin | FDX1                                      |             | ChcoDODAA1   |        | FDX1       |
| pL1ATOP2  | pICH47751 | position 3 fwd | Ampicillin | PSAD                                      | Riboswitch1 | ChcoCYP76AD6 |        | PSAD       |
| pL1ATOP3  | pICH47761 | position 4 fwd | Ampicillin | HSP70::RBCS2                              | Riboswitch2 | ChcoCYP76AD1 |        | CA1        |
| pL1ATOP4  | pICH47751 | position 3 fwd | Ampicillin | HSP70::RBCS2                              | RBCS2(i)    | ChcoCYP76AD6 |        | CA1        |
| pL1ATOP5  | pICH47761 | position 4 fwd | Ampicillin | HSP70::RBCS2                              | RBCS2(i)    | ChcoCYP76AD1 |        | CA1        |
| pL1ATOP6  | pICH47772 | position 5 fwd | Ampicillin | RPL23                                     |             | ChcocDOPA5GT |        | RPL23      |
| pL1ATOP9  | pICH47742 | position 2 fwd | Ampicillin | FDX1                                      |             | ChcoDODAA1   |        | RPL23      |


## Level 2

| Vector ID        | Backbone  | Resistance | Level 2              |                     |                                    |                                       |                          |                         |
|------------------|-----------|------------|----------------------|---------------------|------------------------------------|---------------------------------------|--------------------------|-------------------------|
|                  |           |            | position 1           | position 2          | position 3                         | position 4                            | position 5               | position 6              |
| pL2ATOP1 (pBET)  | pICSL4723 | Kanamycin  | PSAD/BleR/PSAD (rev) | FDX1/ChcoDODA/RPL23 | PSAD/Riboswitch1CYP76AD6/PSAD      | HSP70::RBCS2/Riboswitch2/CYP76AD1/CA1 | RPL23/ChcocDOPA5GT/RPL23 | HSP70::RBCS2/ParR/RBCS2 |
| pL2ATOP3 (pBCY+) | pICSL4723 | Kanamycin  | PSAD/BleR/PSAD (rev) | FDX1/ChcoDODA/RPL25 | PSAD/CTP/ChcoADHa/PSAD             | HSP70::RBCS2/RBCS2(i)/CYP76AD1/CA1    | RPL23/ChcocDOPA5GT/RPL23 | HSP70::RBCS2/ParR/RBCS2 |
| pL2ATOP5 (pBTX+) | pICSL4723 | Kanamycin  | PSAD/BleR/PSAD (rev) | FDX1/ChcoDODA/RPL27 | HSP70::RBCS2/RBCS2(j)/CYP76AD6/CA1 | PSAD/CTP/ChcoADHa/PSAD                | Dummy                    | HSP70::RBCS2/ParR/RBCS2 |

**Table 2.** Detailed level 2 design for each of the constructed vectors. pBET is the vector containing riboswitches for CYP76AD1 and CYP76AD6. pBCY and pBTX are vectors designed to produce betacyanins (red) and betaxanthins (yellow) respectively.

| Vector ID |          | Position 1 |      |      | Position 2 |      |       | Position 3  |             |          |      | Position 4  |             |          |     | Position 5 |          |       | Position 6  |     |       |
|-----------|----------|------------|------|------|------------|------|-------|-------------|-------------|----------|------|-------------|-------------|----------|-----|------------|----------|-------|-------------|-----|-------|
|           |          | Ter        | CDS  | Pro  | Pro        | CDS  | Ter   | Pro         | RS          | CDS      | Ter  | Pro         | RS          | CDS      | Ter | Pro        | CDS      | Ter   | Pro         | CDS | Ter   |
| pBET      | pL2ATOP1 | PSAD       | BleR | PSAD | FDX1       | DODA | RPL23 | PSAD        | Riboswitch1 | CYP76AD6 | PSAD | HSP70:RBCS2 | Riboswitch2 | CYP76AD1 | CA1 | RPL23      | cDOPA5GT | RPL23 | HSP70:RBCS2 | PaR | RBCS2 |
| pBCY      | pL2ATOP2 | PSAD       | BleR | PSAD | FDX1       | DODA | RPL23 | Dummy       |             |          |      | HSP70:RBCS2 | intron      | CYP76AD1 | CA1 | RPL23      | cDOPA5GT | RPL23 | HSP70:RBCS2 | PaR | RBCS2 |
| pBTX      | pL2ATOP4 | PSAD       | BleR | PSAD | FDX1       | DODA | RPL23 | HSP70:RBCS2 | intron      | CYP76AD6 | CA1  | Dummy       |             |          |     | Dummy      |          |       | HSP70:RBCS2 | PaR | RBCS2 |

**Figure 1.** PCR performed to isolate 5' and 3' flanking regions for RPL23, RPL35 and FDX1 from *C. reinhardtii* genomic DNA. A, promoter region using primers with 3' overhang TACT; B, promoter region using primers with 3' overhang AATG; Ter, terminator region. White squares indicate right sized bands.



**Figure 2.** Diagnostic digestions for level 2 vectors. Numbers correspond to different plasmid extracted from independent colonies. pBET and pBCY were digested with *NheI*. pBTX was digested with *EcoRI*. Asterisks correspond to correct expected digestion patterns.

